Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Tabuchi,Satoshi; Ozawa,Soji; Koyanagi,Kazuo; Shigematsu,Naoyuki; Kubo,Atsushi; Ueda,Masakazu; Kitagawa,Yuko; Kitajima,Masaki

doi:10.3892/etm.2011.263

Radiation-sensitizing effect of low-concentration docetaxel on human esophageal squamous cell carcinoma cell lines

Authors:
- Satoshi Tabuchi
- Soji Ozawa
- Kazuo Koyanagi
- Naoyuki Shigematsu
- Atsushi Kubo
- Masakazu Ueda
- Yuko Kitagawa
- Masaki Kitajima
View Affiliations

Affiliations: Department of Surgery, School of Medicine, Keio University, Tokyo, Japan, Department of Gastro-enterological Surgery, Tokai University School of Medicine, Isehara, Kanagawa 259-1193, Japan, Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan, Department of Pathology, School of Medicine, Keio University, Tokyo, Japan
Published online on: May 10, 2011 https://doi.org/10.3892/etm.2011.263
Pages: 601-606

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Esophageal squamous cell carcinoma (ESCC) is more sensitive to radiation and chemotherapy than other cancers of the digestive system, and combined modality therapy may represent a promising treatment method. The radiation-sensitizing effect of docetaxel on ESCC cell lines was investigated. A colony formation assay was performed in which ESCC cell lines (TE2, TE3) and A431 were exposed to docetaxel (from 1.0x10-11 to 10-7 M) for 3 h to determine the concentration of docetaxel that was not able to kill individual cells (i.e., the non-cytocidal concentration). Individual cell lines were then exposed to the non-cytocidal concentration of docetaxel prior to, during, and after irradiation to determine whether the timing of docetaxel administration affected cell survival. In addition, flow-cytometry was performed, and the cell cycle was examined prior to and after docetaxel exposure to assess the mechanism of docetaxel as a radiation sensitizer. Docetaxel exhibited a concentration-dependent cytocidal effect, with a different IC50 for each cell type. Almost no cytocidal effect was observed at the following docetaxel concentrations: A431, ≤1.0x10-10 M; TE-2 and TE-3, ≤1.0x10-9 M. Concurrent treatment with docetaxel and radiation tended to decrease cell survival in all the cell lines compared with docetaxel or radiation alone. Cell survival was lowest when the cells were treated using X-ray irradiation after docetaxel exposure (p<0.05). Flow cytometry revealed that in all three cell lines, docetaxel exposure increased the G2/M cell fraction with a higher increase in the cell line that exhibited the highest radiosensitivity. This study demonstrated that the administration of docetaxel at a non-cytocidal concentration prior to radiotherapy produced a synergistic cell-killing effect in SCC cell lines.

View Figures

View References

1.	Herskovic A, Martz K, Al-Sarraf M, et al: Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 326:1593–1598. 1992. View Article : Google Scholar : PubMed/NCBI
2.	Al-Sarraf M, Martz K, Herskovic A, et al: Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol. 15:277–284. 1997.PubMed/NCBI
3.	Cooper JS, Guo MD, Herskovic A, et al: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
4.	Coia LR, Minsky BD, Berkey BA, et al: Outcomes of patients receiving radiation for cancer of the esophagus: results of the 1992–1994 patterns of care study. J Clin Oncol. 18:455–462. 2000.PubMed/NCBI
5.	Ando N, Iizuka T, Ide H, et al: Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol. 21:4592–4596. 2003. View Article : Google Scholar : PubMed/NCBI
6.	Ringel I and Horwitz SB: Studies with RP 56976 (Taxotere): a semisynthetic analogue of taxol. J Natl Cancer Inst. 83:288–291. 1991. View Article : Google Scholar : PubMed/NCBI
7.	Garcia P, Braguer D, Carles G, et al: Comparative effects of taxol and taxotere on two different human carcinoma cell lines. Cancer Chemother Pharmacol. 34:335–343. 1994. View Article : Google Scholar : PubMed/NCBI
8.	Hanauske AR, Degen D, Hilsenbeck SG, Bissery MC and von Hoff DD: Effects of taxotere and taxol on in vitro colony formation of freshly explanted human tumor cells. Anticancer Drugs. 3:121–124. 1992.
9.	Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol. 5:533–537. 1994.
10.	Couteau C, Chouaki N, Leyvraz S, et al: A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 81:457–462. 1999. View Article : Google Scholar : PubMed/NCBI
11.	Bang YJ, Kang WK, Kang YK, et al: Docetaxel 75 mg/m² is active and well tolerated in patients with metastatic or recurrent gastric cancer: a Phase II Trial. Jpn J Clin Oncol. 32:248–254. 2002.
12.	Dreyfuss AI, Clark JR, Norris CM, et al: Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol. 14:1672–1678. 1996.PubMed/NCBI
13.	Mauer AM, Masters GA, Haraf DJ, et al: Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol. 16:159–164. 1998.PubMed/NCBI
14.	Matsuura M, Hasegawa M, Hayakawa K, et al: Experimental study of the effects on apoptosis of docetaxel alone and in combination with irradiation. Oncol Rep. 7:289–293. 2000.PubMed/NCBI
15.	Kim ES and Khuri FR: Docetaxel and radiation as combined-modality therapy. Oncol (Williston Park). 16(Suppl 6): 97–105. 2002.PubMed/NCBI
16.	Fujii M, Tsukuda M, Sakata B, et al: Japan Cooperative Head and Neck Oncology Group (JCHNOG). Phase I/II trial of weekly docetaxel and concomitant radiotherapy for squamous cell carcinoma of the head and neck. Int J Clin Oncol. 9:107–112. 2004. View Article : Google Scholar : PubMed/NCBI
17.	Koukourakis M, Kourousis C, Kamilaki M, et al: Weekly docetaxel and concomitant boost radiotherapy for non-small-cell lung cancer. A phase I/II dose escalation trial. Eur J Cancer. 34:838–844. 1998. View Article : Google Scholar : PubMed/NCBI
18.	Segawa Y, Kiura K, Takigawa N, et al: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol. 28:3299–3306. 2010. View Article : Google Scholar
19.	Choy H, Rodriguez F, Koester S, et al: Synergistic effect of taxol/taxotere on radiation sensitivity on human tumor cell lines. Int J Radiat Oncol Biol Phys. 24(Suppl): 274–275. 1992. View Article : Google Scholar
20.	Pradier O, Rave-Fränk M, Lehmann J, et al: Effects of docetaxel in combination with radiation on human head and neck cancer cells (ZMK-1) and cervical squamous cell carcinoma cells (CASKI). Int J Cancer. 91:840–845. 2001. View Article : Google Scholar : PubMed/NCBI
21.	Hennequin C, Giocanti N and Favaudon V: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 56:1842–1850. 1996.PubMed/NCBI
22.	Creane M, Seymour CB, Colucci S and Mothersill C: Radiobiological effect of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol. 75:731–737. 1999. View Article : Google Scholar : PubMed/NCBI
23.	Mason KA, Hunter NR, Milas M, Abbruzzese JL and Milas L: Docetaxel enhances tumor radioresponse in vivo. Clin Cancer Res. 3:2431–2438. 1997.PubMed/NCBI
24.	Mason KA, Kishi K, Hunter N, et al: Effect of docetaxel on the therapeutic ratio of fractionated radiotherapy in vivo. Clin Cancer Res. 5:4191–4198. 1999.PubMed/NCBI
25.	Shigematsu N, Kawata T, Ihara N, et al: Effect of combined treatment with radiation and low dose etoposide on cell survival. Anticancer Res. 21:325–328. 2001.PubMed/NCBI
26.	Withers HR, Mason K, Reid BO, et al: Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer. 34:39–47. 1974. View Article : Google Scholar : PubMed/NCBI
27.	Hartwell LH and Weinert TA: Checkpoints: controls that ensure the order of cell cycle events. Science. 246:629–634. 1989. View Article : Google Scholar : PubMed/NCBI
28.	Dolbeare F, Beisker W, Pallavicini MG, Vanderlaan M and Gray JW: Cytochemistry for bromodeoxyuridine/DNA analysis: stoichiometry and sensitivity. Cytometry. 6:521–530. 1985. View Article : Google Scholar : PubMed/NCBI